國家衛生研究院 NHRI:Item 3990099045/3006
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2478489      線上人數 : 73
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/3006


    題名: Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients
    作者: Liu, JM;Chen, LT;Chao, Y;Li, AFY;Wu, CW;Liu, TS;Shiah, HS;Chang, JY;Chen, CT;Wu, HW;Lin, WC;Lan, C;Whang-Peng, J
    貢獻者: National Institute of Cancer Research;Division of Biotechnology and Pharmaceutical Research
    摘要: Purpose: A phase 11 and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m(2) as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 mug/ml,which was high compared to the mean peak drug concentration of 6 +/- 4.1 mug/ml. The mean systemic GL331 clearance was 12.1 +/- 7.2 l/h per m(2), much lower than 23.3 +/- 8.2 l/h per m(2) found in the phase I trial. Topoisomerase IIalpha was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.
    關鍵詞: Oncology;Pharmacology & Pharmacy
    日期: 2002-05
    關聯: Cancer Chemotherapy and Pharmacology. 2002 May;49(5):425-428.
    Link to: http://dx.doi.org/10.1007/s00280-002-0429-3
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0344-5704&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000176113700011
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036232644
    顯示於類別:[彭汪嘉康(1996-2007)] 期刊論文
    [陳炯東] 期刊論文
    [劉敏(1996-2007)] 期刊論文
    [夏和雄(1996-2012)] 期刊論文
    [張俊彥] 期刊論文
    [陳立宗] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    000176113700011.pdf75KbAdobe PDF753檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋